Cassava’s Alzheimer’s Drug Fails In First Phase III, Second Pivotal Trial Stopped

SEC Settlement Overhang Remains

After years of controversy, simufilam did not achieve statistical significance on any endpoints in ReThink-ALZ, so the company ended ReFocus-ALZ and its long-term extension study.

Cassava likely has reached the end of the road with simufilam (Shutterstock)

The long and arduous development path for Cassava Sciences’ simufilam in mild-to-moderate Alzheimer’s disease appears to have come to its end now that the drug failed to deliver statistically significant improvements in cognition and function across any of the primary and secondary endpoints in the Phase III ReThink-ALZ clinical trial.

Based on the trial’s results, the company said on 25 November that it will discontinue a second Phase III study,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

What Incyte Investors Expect From New CEO Bill Meury

27 Jun 2025

• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

27 Jun 2025

• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

27 Jun 2025

• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.